SEARCH

SEARCH BY CITATION

References

  • 1
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331338.
  • 2
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558567.
  • 3
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704708.
  • 4
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 5
    Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675681.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 7
    McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140147.
  • 8
    Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341349.
  • 9
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; PEGASYS International Study Group. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 10
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370381.
  • 11
    Liu C, Zhu H, Subramanian GM, Moore PA, Xu Y, Nelson DR. Anti-HCV activity of albinterferon alfa-2b in cell culture. Hepatol Res 2007; 37: 941947.
  • 12
    Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671678.
  • 13
    Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006; 11: 3545.
  • 14
    Ware JE, Kosinski M. The SF-36 Health Survey (version 2.0) Technical Note. Boston, MA: Health Assessment Lab, September 20, 1996 (updates September 27, 1997).
  • 15
    Ware JE, Snow KK, Kosinski MA, Gandek B. SF-36 Health Survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
  • 16
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425433.
  • 17
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 18
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954960.
  • 19
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 20
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704708.